Merck said its Emend drug to prevent chemotherapy-related nausea and vomiting was significantly more effective than a placebo in a Phase III study of cancer patients aged 6 months to 17 years.
from WSJ.com: US Business http://ift.tt/1r6v68n
via IFTTT
from WSJ.com: US Business http://ift.tt/1r6v68n
via IFTTT
No comments:
Post a Comment